Generative Biologics
AI-powered platform for generative design and optimization of biologics.
Executive Summary
Generative Biologics is an advanced, AI-powered platform developed by Insilico Medicine, specifically engineered for the generative design and optimization of various biologic drug candidates, including peptides and nanobodies. It leverages sophisticated artificial intelligence to move beyond simple sequence generation, providing capabilities to score and rank generated molecules based on both classical computational methods and AI-driven predictive models. The platform is an integral part of Insilico's broader Pharma.AI suite, which aims to revolutionize drug discovery and development through end-to-end generative AI. It supports specialized workflows, such as template-based screening of peptide libraries against specific biological receptors, and allows for manual refinement and optimization. By integrating these advanced AI capabilities, Generative Biologics significantly enhances the quality and accelerates the productivity of pharmaceutical research in the biologics space.
Use Cases
- Generative design of novel peptide sequences and structures
- Optimization of nanobody candidates for specific targets
- High-throughput screening of biologic libraries against receptors
- Predictive scoring and ranking of potential biologic drug candidates
- Accelerating hit identification and lead optimization in biologics discovery
Features
Visibility
- Interactive Candidate Visualization: Explore and compare generated biologic candidates with detailed visual representations of their structures and properties.
- Property Analysis View: Access comprehensive analysis of predicted physicochemical properties, binding affinities, and other critical attributes for each candidate.
Intelligence
- De Novo Biologic Generation: AI-driven creation of entirely new peptide and nanobody sequences and structures from scratch.
- Target-Specific Optimization: AI algorithms optimize generated biologics to maximize desired interactions with specific biological targets.
- Peptide Workflow Automation: Automated template-based screening and refinement of peptide libraries against defined receptors.
- Multi-Parameter Scoring: Advanced scoring system that evaluates candidates across multiple criteria, including efficacy, safety, and developability.
Technical Specifications
- Deployment
- SaaS
Pricing
- Starting Price
- Contact sales
- Target Customer
- Enterprise
About Insilico Medicine
Insilico Medicine is a clinical-stage biotechnology company that leverages artificial intelligence and deep learning to accelerate drug discovery and development. The company focuses on therapeutic solutions for cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions, utilizing its proprietary Pharma.AI platform to discover novel targets, design new molecules, and advance candidates into human clinical trials.